Seal Rock Therapeutics, Inc., a US-based clinical stage company, announced on Wednesday that it has signed an out-licensing agreement with GENFIT (Nasdaq:GNFT) (Euronext:GNFT), a France-based biopharmaceutical group, for the development of an injectable formulation of SRT-015 intended for the treatment of acute liver disease, including Acute-on-Chronic Liver Failure (ACLF).
According to the contract, Seal Rock Therapeutics is eligible for payments up to EUR100m including regulatory, clinical, and commercial milestone payments and tiered royalties.
SRT-015 is a highly optimised, second generation, liver-selective inhibitor of Apoptosis Signal-reducing Kinase 1 (ASK1) and is being developed by Seal Rock Therapeutics, in an oral formulation, as a treatment for severe acute alcoholic hepatitis and orphan liver diseases and NASH.
Neil McDonnell, Seal Rock Therapeutics CEO, said, 'We're excited to announce this licensing deal with GENFIT that will accelerate the development of an injectable formulation of our second-generation ASK1 inhibitor SRT-015 for ACLF, a liver disease with high unmet need. At Seal Rock, we remain focused on initiating a Phase 2a trial of oral SRT-015 for severe alcoholic hepatitis. We will also continue development of our first-in-class LRRK2/ASK1 dual kinase inhibitors for Parkinson's Disease and ALS.'
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study